Vijaya Diagnost. Q1 FY27 Earnings Call — Analysis (NSE: VIJAYA)
Vijaya Diagnostic delivers 22.8% revenue growth and 360 bps EBITDA margin expansion, accelerates hub expansion with confidence from successful new centre ramp-ups.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Consolidated Revenue ₹231 Cr ( +22.8% YoY ) .
Results
Consolidated revenue ₹231 Cr +22.8% YoY, EBITDA margin 42.7% (+360 bps), PAT ₹53 Cr +37.6% YoY; test volume growth 16.5%.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹231 Cr | +22.8% | yoy · Q1FY27 |
| Test Volume Growth | 16.5% | +16.5% | yoy · Q1FY27 |
| EBITDA | ₹98 Cr | +34% | yoy · Q1FY27 |
| EBITDA Margin | 42.7% | +360 bps | yoy · Q1FY27 |
| PAT | ₹53 Cr | +37.6% | yoy · Q1FY27 |
| PAT Margin | 23% | point_in_time · Q1FY27 | |
| B2C Revenue Share | 92% | point_in_time · Q1FY27 | |
| Radiology Revenue Share | 37% | point_in_time · Q1FY27 | |
| Revenue per Test | ₹503 | point_in_time · Q1FY27 | |
| Revenue per Footfall | ₹1,860 | point_in_time · Q1FY27 | |
| Cash Surplus | ₹330 Cr | point_in_time · Q1FY27 · As of Jun-26 |
Guidance
Management guides for high double-digit revenue growth in FY27 with capex of ₹190-195 Cr for 9 hubs and 10-12 spokes; expects to sustain EBITDA margins above 40%.
Key themes
Network expansion into new geographies with strong operating leverage
Operational commentary
- Commissioned flagship hub in Bengaluru (JP Nagar) in July with digital PET-CT, 75cm wide-bore 3T Omega MR, and a full-fledged automated central lab to serve as Bengaluru’s central processing facility.
- Added 1 hub centre in Gachibowli, Hyderabad with 160-slice cardiac CT; commissioned 4 spokes across Hyderabad, AP and Pune in Q1, plus 2 more spokes in July.
- Planning to add 9 hub centres and 10-12 spoke centres in the next 12 months, along with a reference laboratory at Panjagutta; capex planned at ₹190-195 Cr, including land acquisition (₹8-10 Cr) for a new AP hub.
- Mature centres grew 16% YoY; new centres contributed 6-6.5% of revenue; combined 10 hubs from FY26 are largely breakeven with total EBITDA drag less than ₹1 Cr.
- Hyderabad revenue grew 17% YoY, Pune grew 18% YoY; wellness revenue share reached 14.8% aided by advanced imaging packages and tier-2 uptake.
- B2C revenue at 92%, radiology share at 37%; tests per patient at 3.7 vs typical pathology chains' 2.5-3, driving higher wallet share and realization per customer.
- No price hike since June 2025; pricing strategy reassessment planned post Q2-Q3.
- Bangalore strategy: after two hubs broke even in Year 1 and JP Nagar central lab in place, Bengaluru will see hub-and-spoke cluster densification, home collection, and a 5-year journey mirroring Hyderabad.
Analyst Q&A
Q. Will the elevated Q1 margins sustain despite expansion, and what is the margin outlook?
Operating leverage from existing clusters plus minimal drag from new hubs (0.5% of top line in FY26) gives confidence of maintaining above 40% EBITDA margin even with an additional 1-1.5% drag from FY27 expansion.
Q. Is the land purchase in AP a deviation from the lease-only strategy?
It is a one-off exception for a key medical hub where a suitable lease has not been available for 6-7 years; the investment is ₹8-10 Cr, included in the ₹190-195 Cr capex.
Q. How is the competitive landscape in Bangalore and can it become as large as Hyderabad?
Bangalore's competitive landscape is fragmented with no large multi-centre chain; Vijaya's JP Nagar hub brings first-in-market imaging, and Bangalore-Karnataka is expected to be a core geography as deep as Hyderabad over 10-15 years.
Q. Is there any plan to monetize the healthcare data accumulated?
Data is recognized as a goldmine but currently not shared due to compliance ambiguity; strict privacy policy is in place and monetization will be evaluated only after appropriate regulatory clarity.
Q. What was the absolute EBITDA loss from new centres in Q1?
The burn from the 3-4 hubs that haven't yet broken even is less than ₹1 Cr for the quarter.
Research and educational content only. Not investment advice.